Skin News and Research

RSS

Growth-braking tumor-suppressor gene slows growth of childhood brain tumors

Johns Hopkins researchers have found a likely explanation for the slow growth of the most common childhood brain tumor, pilocytic astrocytoma. Using tests on a new cell-based model of the tumor, they concluded that the initial process of tumor formation switches on a growth-braking tumor-suppressor gene, in a process similar to that seen in skin moles.

24 Jun 2011

Patients with familial adenomatous polyposis have higher vascular density in mouth

A team led by Johns Hopkins researchers has found that a hereditary colon cancer syndrome, familial adenomatous polyposis (FAP), is associated with abnormally dense blood vessel growth in the skin lining the mouth.

24 Jun 2011

Summer safety tips to keep kids safe

Summer fun is in full swing, which coincides with an increase in bumps, bruises, scrapes and possibly worse. To keep kids safe, prevention and first-aid should be at the forefront of parents' minds this summer according to Dr. Karen Judy, Loyola University Health System pediatric safety expert and professor of pediatrics at Loyola University Chicago Stritch School of Medicine.

23 Jun 2011

MEDA seeks marketing authorization for Zyclara in Europe

“Zyclara will strengthen Meda's dermatology franchise in Europe. We look forward to provide AK patients with a new product that can treat larger areas of the skin”

23 Jun 2011

HKU releases draft genome sequence of scarlet fever strain

Scarlet fever has revealed unusual high infect rate in Hong Kong this year. So far, 466 children were infected and 2 of them dead. Scarlet fever is caused by Streptococcus pyogenes, a gram-positive pathogen that can be transmitted via skin wound and airborne droplet.

23 Jun 2011

FDA approves ProStrakan's Rectiv for pain associated with anal fissures

ProStrakan Group plc, a subsidiary of Kyowa Hakko Kirin Co. Ltd., and an international specialty pharmaceutical company, today announces that it has received approval from the U.S. Food and Drug Administration (FDA) for Rectiv™ (nitroglycerin) Ointment 0.4 % for the treatment of moderate to severe pain associated with chronic anal fissures.

22 Jun 2011

Nine young clinical investigators earn recognition from Damon Runyon Cancer Research Foundation

The Damon Runyon Cancer Research Foundation named five new Damon Runyon Clinical Investigators at its spring 2011 Clinical Investigator Award Committee review.

22 Jun 2011

Reduced levels of VAPB protein may play central role in causing ALS

An international team of scientists led by researchers at the University of California, San Diego School of Medicine have used induced pluripotent stem cells (iPSCs) derived from patients with amyotrophic lateral sclerosis (ALS) to reveal for the first time how reduced levels of a specific protein may play a central role in causing at least one inherited form of the disease.

22 Jun 2011

Tips for protecting your skin from sun's harmful rays

Summer is here and for many that means enjoying more outdoor activities. While it's important to remember sun safety, from time-to-time sunburns are bound to happen. Covenant Health System would like to promote sun safety and offer some useful remedies for dealing with sunburns.

22 Jun 2011

Kid’s allergies estimated to be more prevalent than thought

It is found that food allergies in children might be more common than some previous research has suggested. A new study estimates that about 8% of children, about 6 million in the U.S., have a food allergy. Not only is this estimate higher than some previous research has reported, the study found that reported allergic reactions are often severe and that many kids have more than one allergy.

21 Jun 2011

New anti-abuse formulation of painkiller Oxycodone

It has come to health officials’ attention nationwide that there is a serious rise of abuse of painkillers, especially opioids. Federal officials recently stepped up plans to monitor frequent prescribers and users.

21 Jun 2011

Wayne State team receives $330,000 NSF grant to develop 3-D neural probe for tinnitus

A team of Wayne State University researchers was awarded $330,000 from the National Science Foundation (NSF) to develop a 3-D neural probe. Their aim is to develop an implantable device that will suppress tinnitus, a neurological disorder that affects more than 250 million people worldwide.

21 Jun 2011

U.S. FDA approves generic Levaquin for treatment of bacterial infections

The U.S. Food and Drug Administration today approved the first generic versions of Levaquin, an antibiotic approved to treat certain infections in people ages 18 and older.

21 Jun 2011

Experts help raise awareness about dangers of melanoma in the U.S.

San Diego is one of the top 10 sunniest cities in the United States. Even when "June Gloom" clouds our skies, the sun is still very powerful. With that in mind, experts with UC San Diego Moores Cancer Center are helping raise awareness of the dangers of melanoma, the most serious type of skin cancer.

21 Jun 2011

Contaminated cocaine may lead to public health epidemic

Doctors warned of a potential public health epidemic in a recent report on patients in Los Angeles and New York who developed serious skin reactions after smoking or snorting cocaine believed to be contaminated with a veterinary medication drug dealers are using to dilute, or "cut," up to 70% of the cocaine in the U.S.

20 Jun 2011

Photocure launches Photodynamic Cosmetic for improving skin appearance

Photocure, the world leader in photodynamic technology today announced the commercial launch of Allumera in the US, the first Photodynamic Cosmetic specifically formulated to improve the overall appearance of skin, reduce outward signs of aging and minimize the appearance of pores with minimal downtime and results that last.

20 Jun 2011

Positive results from vismodegib Phase II study on advanced basal cell carcinoma

Genentech, a member of the Roche Group, announced today that a pivotal Phase II study with vismodegib showed positive results in people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

20 Jun 2011

Genentech to present positive data from vismodegib Phase II trial on advanced BCC at EADO 2011

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that positive data are being presented by its collaborator Genentech, a member of the Roche Group, from a pivotal Phase II clinical trial conducted by Roche and Genentech of vismodegib in patients with advanced basal cell carcinoma, an often life-threatening form of skin cancer that can have disfiguring and debilitating effects.

20 Jun 2011

MA launches national campaign to raise awareness on meningitis

This Father's Day is a special day for Angels Dads on Meningitis (ADOM). Angel dads from across the country came together in Denver, Colorado to launch a national campaign on meningitis awareness.

20 Jun 2011

PDA urges public to undergo screening for oral cancer

Oral cancer claims more lives than leukemia, Hodgkin's lymphoma, laryngeal cancer, testicular cancer, thyroid cancer, or skin cancer. In 2010, approximately 36,540 Americans were diagnosed with this largely preventable type of cancer that affects the mouth and throat; 7,880 died of the disease. Early detection is essential to dramatically reduce the number of deaths from oral cancer.

18 Jun 2011